Introduction
Fast and efficient computational methods are important for real-time therapy guidance and are a growing trend in Bio-Engineering [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . More recently, significant clinical outcomes have been achieved by table-based glucose control protocols [12] [13] [14] that mimic and are developed from computer-based protocols [15] [16] [17] [18] , but are much simpler to implement and more likely to be accepted by clinical staff [19] . Such model-derived or model-validated approaches are also increasing in prevalence [20, 21] .
Tight control of blood glucose levels gained significant importance in critical care after
Van den Berghe et al. [22] showed reductions in mortality rates of up to 45% are possible. The common way of assessing risk of death in the ICU is by an APACHE score, which measures the severity of illness. Thus, higher scores mean a higher risk of death.
The trials in [12] [13] [14] represent the first model-based or model-derived protocol to report a significant clinical outcome with a 32% mortality reduction [18] , despite significantly high APACHE scores. This trial also had some of the tightest glucose control reported as compared to other studies e.g. [2, 18, [23] [24] [25] [26] [27] [28] [29] , indicating the potential of computational models to impact this field.
A major component in the development of these model-based protocols [13, 14, 18] is the concept of "virtual patient trials" where each new potential protocol is tested in simulation off-line, with up to hundreds of thousands of patient hours [12, 21] . This approach can include Monte Carlo analysis methods, which can add the effects of parameter uncertainty and different sensor errors into the analysis [16, 30] . The major advantage of a "virtual patient" approach is that algorithms and methods can be tested and optimized safely before clinical implementation. Furthermore, the approach gives insight into potential long term clinical performance and provides a repeatable cohort for easy comparison of different protocols [12, 13] . The considerable patient variation and sensor noise combined with different variations in the glucose-insulin physiological modelling can lead to large numbers of simulations required. Thus, a fundamental requirement in this "model-based therapeutics" approach is very fast and accurate simulation methods that can be performed using simple programme languages, such as Matlab, to minimize development time.
A virtual patient database represents a summary of the metabolic changes and interventions for patients in a given cohort over the entire length of stay in the intensive care unit (ICU). The primary parameter used to represent patients' metabolic status [12, 13] was insulin sensitivity ( I S ), which was allowed to vary with time but was held constant over each one hour period. These I S profiles were established from retrospective clinical data using an integral-based parameter identification method [20] .
Data from patients in other trials [15] [16] [17] [18] was also added to this database.
The process of creating a virtual patient cohort and then testing or creating new protocols using the physiological model is referred to here as "model-based therapeutics" (MBT).
This MBT approach led to the development of the Specialized Relative Insulin + Nutrition Tables (SPRINT) protocol that has been implemented in the Christchurch
Hospital ICU [12-14, 18, 31] . Successful initial results have also been obtained in several other areas, including model based cardiac diagnosis [32] [33] [34] [35] [36] , sedative drug delivery [37, 38] and insulin sensitivity measurement [30, 39] .
In all these cases, extensive simulation (Monte Carlo based) is performed in virtual trials to ensure robustness of the protocols developed. Some analyses run as many as 100,000-200,000 patient hours (80-160 patient years) in total [13, 14] . Thus, a fundamental element in the MBT approach must be highly accurate, easily programmable, very fast forward solutions to non-linear physiological models to reduce computational burden and run-time.
To get an idea of the computation time required, the original MATLAB simulation code used to develop the SPRINT system [13, 14] , which originally used 19 patients, takes 0.9 seconds to simulate one patient hour on a PC with a 2.4GHz processor and 2GB RAM.
This simulation uses a maximum step size of 0.019 based on an error analysis to ensure the 90 th percentile error is less than 0.1%. Note that using an error analysis based on reducing the relative error tolerance instead of the maximum step size, would yield faster results of 0.035 s for one patient hour. However, for highly stiff systems (e.g. [36] ), the maximum step size method was found to be a more reliable and conservative option, so was used in the development of SPRINT. In this case, the Monte Carlo (100x) testing of a new protocol on 384 patients (42,000 hours) would require 4,200,000 patient hours × 0.9s = 43.8 days of simulation. As more patients are added, greater numbers of protocols are tested, and potentially more dynamics are added to the glucose-insulin model (e.g. a more detailed carbohydrate input model), then even more significant computing time and resources would be required. Thus, the computational time would significantly limit the number of patients and protocols that could be tested, potentially hindering research and clinical outcomes.
The glucose control protocols discussed [2, 12-17, 40, 41] require a simulated measurement only 1-2 hourly. In contrast, to obtain sufficient accuracy, numerical ODE solvers (e.g. [16] ) compute the glucose value at every time step (minutes or seconds)
throughout an hour. In other words, a large percentage of computation is spent calculating glucose values that are not used in a virtual trial or clinical control. However, the reasonably typical non-linear glucose-insulin model [17] has no direct analytical solution.
Furthermore, other insulin-glucose models reported in the literature, ranging from relatively simple e.g. [42] , to far more complicated [43] , also require computationally intense numerical solutions. Hence, the computational cost of extensive virtual trials simulations yields values that are necessary only for accurate solution by the solver, but
are not used directly in protocol development.
The approach in this research, is to form partial analytical solutions to a subset of the model in terms of simpler approximating functions that are valid within known physiological bounds. These simpler functions then enable an analytical solution to the whole model to be constructed. More specifically, the approach is to reformulate and tailor solutions to the specific application required. With careful construction and the use of known mathematical solutions to differential equations, it is shown that an approximate, but highly accurate, analytical solution can be found to the full non-linear glucose-insulin system model. This solution dramatically increases the forward simulation speed of the model, by avoiding the need to calculate values that are not used in the virtual trial simulations. It thus enables far more rapid development of new protocols using the virtual patient based MBT approach.
Methodology

Model of glucose and insulin kinetics
The model of glucose and insulin kinetics [17] used to run virtual trials in this research originates from Bergman's minimal model [42] . Additional non-linear terms, a more physiologically representative formulation, and time varying insulin sensitivity,
, creates the system model defined [2, [12] [13] [14] [15] [16] [17] 40] :
( )
where eq G is the equilibrium plasma glucose concentration and G is the plasma glucose concentration above eq G . The exogenous feed input rate is denoted ( ) Thus, Equation (4) is essentially the analytical solution to the 2 compartment system in [16, 17] . Note that ( ) t P is defined as mmol/L/min, accounting for the glucose distribution literature search and eq G is estimated from the moving mean glucose concentration during a patient's stay [17, 20] . The parameter S I is patient specific. Note that for simplicity, the model is reformulated by replacing G by G total -G eq in Equation (1):
Virtual patient cohort
For this research, 17 uncontrolled patients from the study in [20] and 51 controlled patients in the original pilot study of the SPRINT system [13, 14] were used to form the virtual patient cohort. Each patient's physiology was summarized by their insulin sensitivity profile ( ) t S I , which was obtained using the integral based parameter identification method of [20] and the retrospective data.
Given new nutritional and insulin inputs, the virtual patient's ( ) t S I profile can be used in Equations (2)- (5) to generate a (new) set of glucose levels for these different interventions, which is referred to as a "virtual trial" [12, 44] . Different protocols can then be applied on a specific patient by changing the nutritional and insulin inputs for the identified ( ) t S I profiles. Thus, potential improvements to a current retrospective protocol can be tested without requiring a full clinical trial. Therefore, for any new clinical trial, a protocol could be shown to be 'safe' and robust, as well as being optimized for the best possible clinical outcomes.
Analytical solution to insulin I(t) without saturation
In the ICU, for a given hour, the exogenous insulin input u ex (t) in Equation (3) 
If the saturation parameter α I is set to 0, Equation (3) has an analytical solution: 
I t I t t I t t
( 1)
The solution in Equations (7)- (9) will serve as an initial approximation to the solution of Equation (3) with 0 I α ≠ .
Iterative analytical solution I(t) with saturation
For a given approximation, I approx (t) to I(t), Equation (3) can be approximated by:
where α(t) is a known function of time. However, Equation (10) . Thus, the approach is to approximate α(t) in Equation (11) by an integrable function, then Equation (10) can be solved by the integrating factor.
Insulin solution in the first minute
In the first minute, I approx (t) in Equation (11) is replaced by I b (t) of Equation (9), which yields:
The integrating factor of Equation (10) with ( ) ( )
The analytical solution to Equation (10) in the first minute is thus:
There is no closed form solution to the integral in Equation (14) 
where from the trapezium rule:
Using Equation (16) 
where a 2 , b 1 and b 2 are defined in Equation (17).
Insulin solution after first minute
After the first minute, I approx (t) in Equation (11) is replaced by 0 ( )
in Equation (7), which yields:
To enable Equation (22) (1)
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where Equation (24) is an equivalent form of Equation (23) that satisfies (1) (1)
Note that the form of Equations (23) and (24) is motivated from the analytical solution of Equation (8) with two extra polynomial terms added to account for saturation. The approximation also settles at an equilibrium value as t → ∞ , which matches the expected physiology. This approach follows the general philosophy presented in this paper which is to generate approximations that are valid within known physiological constraints and behaviour. Substituting three values of
into Equation (24) A b
where: Since the insulin response is evaluated over 60 minutes, 3 60 t = . The values of t 1 and t 2 need to be chosen carefully to take into account different insulin clearance rates n, and this process is explained in a later section. Equation (26) 21  22  11  12  11  12  1  2  3  31  32  31  32  21  22 det , det , det
where A 2 and A 1 are defined recursively to minimise computation. Once A 1 , A 2 and A 3 are known, a 0 ,…,a 3 are determined from Equation (25) . Hence the integrating factor of Equation (10) with ( ) ( )
in Equation (22) is approximated by: ( ) ( int ( ) 
The motivation for the form of Equation (34) comes from the fact that, when t=t k , in Equation (34) 
where:
Replacing A with C, β with γ and b with d in Equations (28)- (30) yields the closed form solution to C 1 , C 2 , C 3 in Equation (38) .
in Equation (34), the analytical solution to Equations (10) and (11) after 1 minute based on the integrating factor can be approximated by: 
where Equation (41) is derived from integrating Equation (34) from t=1 to t.
Iterative solution
For a given initial insulin approximation 0 ( )
from Equations (7)- (9), which corresponds to no saturation, Equations (20), (21) and (40) give an approximation to the solution of Equation (3) with saturation. This approximation can then be improved by replacing I approx (t) in Equation (11) with the piece-wise linear approximation of insulin in the first minute given by Equations (20), (21) and replacing I approx (t) by Equation (40) after 1 minute. Equations (20), (21) and (40) will then define a new approximation which can again be substituted into Equation (11) and so on. In practice this process could be continued until the relative percentage change is less than a tolerance. However, simulations over all physiological ranges of parameters show that only 2 iterations are necessary. Therefore the algorithm is summarised with 2 iterations as shown in Figure 1 .
Step 1: Define parameters n, α I , I 0 , u i , u b . Set parameters t 1 ,t 2 ,t 3 which are used in Equations (27) and (36).
Step 2: Evaluate from Equations (7) and (8).
Step 3: Evaluate α α α from Equation (12), and
Step 4: Evaluate I b,approx (0.5) and I b,approx (1) using Equations (17)-(21).
Step 5: Evaluate β from Equation (27) , A 1 , A 2 , A 3 from Equations (28)- (30) and thus a 0 , a 1 , a 2 , a 3 from Equation (25) Step 6: (32) and (33)
from Equation (31) and γ from Equation (39) . In Equations (28)- (30), replace A with C, β with γ and b with d to obtain C 1 , C 2 , C 3 which will solve Equation (38)
Step 7: Calculate B 0 , B 1 , B 2 , B 3 from Equation (37), and thus compute I i,approx (t 1 ), (40) and (41).
Step 8 
Step 7. Repeat Steps 3-7
Step 9: Output the new updates to , 
which characterize the main features of the solution to Equation (3) Figure 1 : Algorithm for solving Equation (3) for insulin I(t)
Analytical Solution Q(t)
Given the discrete function evaluation, I b,approx (1) 
, , , , , , a a a a a a a a ≡ in Equation (25) with (1) i α replaced , (28)- (30) with , ,
For generality, Equation (4) is rewritten in the form:
where k 2 = k in this case.
To approximate the solution Q(t) of Equation (44), I(t) is defined: 
where I 0 is the given initial condition of I(t) at t=0. With Equation (45) and   2  0 1  3 , , , a a a a in Equation (43) , Equation (44) can be readily solved for Q(t) in Maple which yields: ( 1) ( ( 1) (1)) ) (47)- (49) gives an approximation of the solution to ( ) Q t in Equation (2).
Glucose solution at 60 minutes
Equation (5) is first re-written in the form:
( ) Q t is defined in Equations (46)- (49) The integrating factor of Equation (49) is defined:
The interstitial compartment of Equation (2) essentially acts like a low pass filter, so that the sharp peak insulin response I(t) in the blood plasma is significantly smoothed out.
Thus, compared to ( ) I t in Equation (45) 
where the nonlinear term is added to approximately account for saturation. Note that a pure quartic was found to be not suitable for Equation (53) as it had significant oscillations. Higher order approximations had similar problems, and require 20+ evaluations of ( ) Q t and least squares to ensure a robust solution. Hence, the form of approximation in Equation (53) is important for minimizing computational cost and represents the most minimal model that gave satisfactory results.
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where Equations (55) are written in recursive form for computational efficiency. An approximation to Equation (52) is thus defined: 
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where ij t is defined in Equation (56), ( ) G t µ is defined in Equation (58), 
Adaptive choice of time points
The time points 1 2 , t t in Equation (27) and (39) and 1 2 3,, t t t in Equations (55)-(61) need to be chosen carefully to maximize accuracy.
Choice of 1 2 , t t in Equation (27) and (39)
The time points 1 2 , t t in Equation (27) and (39) 
An approximation to the insulin decay is thus defined: (7)- (9), with parameters defined in Equation (65)
The steady state value of ˆ( ) i I t in Equation (66) is given by:
The two time points 1 t and 2 t are defined: (68), is that they automatically account for differences in the clearance parameter n which can change significantly between patients [30] . Thus, the approximation of Equation (42) is essentially independent of the clearance n , ensuring a robust and accurate solution, that can adapt to different patients.
Choice of 1 2 3,, t t t in Equation (56)
The time points 1 2 3,, t t t in Equation (56) are associated with the rise and decay of the interstitial insulin ( ) Q t . The key feature in ( ) Q t which can change significantly between patients is the time of the peak. This peak time is affected by both the clearance n and the effective insulin life parameter k in Equations (2) 
In Maple, solving Equations (2) and (3) for ( , 1 ) Q t t ≥ , with the parameters in Equation (65), then solving ( ) 0 Q t =  for t, yields an approximation to the ( ) Q t peak time:
The three time points 1 
The approximation in Equation (74) accounts for significant shifts in the peak time of ( ) Q t due to changes in n and k. Thus, the approximation in Equation (53) automatically adapts to different parameters ensuring a robust and consistent solution to ( ) Q t .
Summary of algorithm
The following flow chart in Figure 2 summarises each step of the analytical algorithm which solves Equations (2)- (5) for each insulin and feed input on the hour. (2)- (5).
Input Parameters: , , a a a a from Equations (55)-(57), 2 3 4 , , µ µ µ from Equations (61) (63) and (64) The algorithm of Figure 2 is applied every hour in this study, to produce the glucose response from a given insulin bolus and/or infusion, nutritional infusion and identified insulin sensitivity for that hour. The parameters n and k are assumed constant for a given patient. Hence, a number of variables in the algorithm of Figure 2 can be pre-computed before the full simulation from hour to hour to reduce computation. These pre-computed variables are summarized:
• Pre-compute 1 2 , t t from Equations (68)- (71), β from Equation (27) and
from Equations (28)- (30) • Pre-compute { } • Pre-compute 
More general model
The insulin Equations (2) and (3) are decoupled and can be solved independently to the glucose Equation (5) . One physiological mechanism that can couple insulin to glucose is endogenous insulin production (EIP), which typically increases as blood glucose increases. In a type 2 diabetic this mechanism is still present, but is significantly less effective at controlling glucose [45] .
The infusion of insulin is known to suppress EIP [46] , and in type 1 diabetes there is no EIP. In critical care insulin is continuously infused, and thus the model of Equations (2)- (5) is appropriate in these cases. However, to allow the possibility of more complex models that account for EIP-glucose coupling which could occur in non-insulin dependent diabetes, or in cases where no insulin is present, a more general model is considered. This model is also presented to demonstrate that the methods developed in this paper are generalizable. The new model is defined:
where ( ) P t is defined in Equation (4). The form of Equations (75)- (77) is based loosely on the physiological model of [30] , but in this case EIP is assumed to be proportional to glucose to create a glucose-insulin coupling. The purpose of this model is purely to test the methods, therefore, the physiological justification and interpretation of parameters is not given here, see [30] for more details.
To allow the algorithm of Figure 2 to be used directly to solve Equations (75)- (77), the Equations of (76) and (77) are reformulated and approximated by: 
where ˆm ax t is defined in Equation (73). The algorithm for solving Equations (75), (78) and (79) is given in Figure 3 . Note that more accurate higher order polynomial approximations to G and Q in Equation (76) could be readily included by re-computing
Equations (15), (20), (21) and Equations (40) and (41), using ˆ( ) ext u t in Equation (80) rather than ( ) ext u t in Equation (6) . All other equations would remain the same. However, it has been found in simulation that constant approximations to mean G and mean Q are more than adequate for approximating the solution to Equations (75)- (77), with errors in glucose typically less than 0.4%. In addition, the main purpose of this section is to show the generalizable ability of the overall approach to other glucose-insulin systems, which the example of Equations (75)- (81) achieves.
Step 1: Set
Step 2: Solve Equations (75), (78) and (79) using the algorithm of Figure 2 with ( ) b t α and ( ) i t α in Equations (12) and (22) replaced byˆ( ) t α in Equation (80); i u in Equation (6) replaced by 3 2 ( ) mean mean V n Q n G + from Equation (80); 2 k in Equation (44) replaced by 2 k in Equation (79).
Step 3: Output ) (ˆm ax Q t , (60) Q and (60) total G from Step 2
Step 4: Approximate mean G and mean Q in Equation (81) by Equation (82) Step 5: Repeat Steps 2-4 until (60) total G changes by less than a given tolerance (78) and (79) 3 Results
Uncontrolled virtual patients
In the retrospective trial of 17 ICU patients in [20] the patients were effectively uncontrolled due to insulin being administered "ad-hoc" by clinical staff using their own discretion and experience. The insulin sensitivity profiles obtained thus represent highly dynamic changes in patient's metabolic systems, with significantly large changes in glucose levels. These variations can be simulated by solving Equations (2)- (5), using the same insulin and nutrition inputs given by clinical staff, providing a virtual retrospective clinical trial. A virtual trial on uncontrolled patients thus provides a test of the flexibility and robustness of the analytical solution to capture highly variable physiological changes in patients, and to control them clinically. from the ICU cohort of [20] using the recorded insulin infusion profile which contained no boluses. Also shown is the glucose measurement points with 7% error bars and the time-varying insulin sensitivity. The insulin sensitivity was found using the parameter identification method detailed in [20] . This method of identifying insulin sensitivity has been validated against the glucose clamp in clinical trials [30] , hence the profile in Figure   4 is a realistic representation of the variability in the patient's physiology. For further details on the parameter identification method see [20] . The reference glucose curve in the upper panel of Figure 4 is generated by solving the full glucose model of Equations (2)- (5) for each hour with an insulin sensitivity given in the lower panel. The carbohydrate and insulin inputs were recorded by nursing staff [20] and also change every hour. Figure 4 shows that the model accurately captures the measured glucose values and the mean absolute relative percentage error between the glucose curves is 0.036% with a 90 th percentile of 0.056%. These values are well within measurement errors of 7-10% and less than 100x smaller. Thus, the numerical and analytical solutions are, clinically, effectively identical.
Note that the large oscillations in glucose are primarily caused by significant changes in patient condition which are reflected by the large changes in I S in the bottom panel of Figure 4 . The problem is that I S changes before nursing staff realize so that when they react to it, I S can change again so they will over (or under) respond. For a full analysis of these effects and the variability that can occur in I S , insulin dosing and carbohydrates see [44] . Table 1 shows the statistics of the absolute relative percentage error between the numerical simulation and the analytical method described in this paper, for the entire 17 patient cohort. All patients were simulated with two different interventions. First, with only constant infusion inputs of insulin over 1 hour periods, which were the actual infusions given by the clinical staff [20] . The second intervention used a random bolus insulin input each hour of between 0 and 6 U to further test the method. Simulations were profile, for example Figure 4 gives the ( ) I S t profile using patient 87. For more details on how much I S can change for patients in an ICU, see [20] .
Over the whole cohort, the mean absolute relative error was found to be very small in both cases, especially for the simulation receiving insulin through a constant infusion.
The mean absolute relative error for the simulation with only bolus insulin input, was found to be slightly larger, which is due to the Michaelis Menten saturation term in Equation ( A random assortment of individual patient results is shown in Tables 2 and 3 for either infusion or bolus control methods. Results for these individual patients are similar to the overall results in Table 1 , with the errors for the infusion based case a factor of 3-4 times smaller than that of the bolus based case. 
SPRINT trial patients
These simulations are used to show that the methods can handle the significant variations in the input of insulin and nutrition regimes that occur with SPRINT and/or in the development of new improved protocols. The first test is to compare the accuracy of the analytical method retrospectively on a 51 patient SPRINT cohort [13, 14] . First, the a priori known ( ) I S t profiles, and insulin and nutrition inputs of the 51 patients are used to forward simulate Equations (2)- (5) using both the analytical and numerical methods to assess the accuracy of this method. These values pre-define the parameters in the hourly cycle of the algorithm of Figure 2 . Table 4 shows the per patient relative absolute percentage error results between the two methods for a random selection of 5 patients. Similar results to the patients in the 17 patient ICU cohort are obtained with very minimal errors. Table 5 shows the statistics for the entire 51 SPRINT patient cohort with all errors below 0.1%. 
Random changes of all parameters
To further validate the method, all the parameters , , , 
Note that, Tables 1-5 show that significant changes in the parameters of Equation (84) have little effect on the accuracy of the analytical solution method presented, so the test in this section investigates the effects of changes in the remaining parameters. 1000 monte carlo simulations were performed and the median error in the glucose value at 60 minutes was 0.046% with a 90 th percentile of 0.14%. Figure 5 plots a histogram of the errors which is significantly skewed to the right, and thus shows that the method is very robust and accurate over all physiological ranges of the parameters. The speed of the algorithm was tested on a PC with a 2.4GHz Pentium 4 processor and 2Gb of RAM. The original numerical simulation code used to develop the SPRINT protocol [13, 14] was first run using Matlab's ode45 differential equation solver. The new analytical method was then run on the same machine. Both algorithms are implemented to simulate a patient hour cycle, given predefined parameters every cycle. The overheads for inputting the parameters and storing the hourly measurement data are thus effectively identical for both simulation methods. Thus, any the differences in the processor execution time (CPU time) between methods should be independent of the input/output overheads.
The step size for Matlab's ode45 was based on an error analysis using patient 87 in Figure 4 with the same random bolus inputs used in Table 3 . The "true" solution was assumed to be the numerical solution with a very small maximum relative tolerance As can be seen in Figure 6 , the error response is very noisy and doesn't reliably settle to less than 0.1% error until the relative error tolerance is less than 0.5e-5. Hence a value of 0.1e-5 was chosen to ensure the 90 th percentile error is always less than 0.1%. From Tables 1-5 , the analytical solution has a 90 th percentile that is typically well less than 0.1%. Hence choosing the relative error tolerance of 0.1e-5 in the numerical solver provides a fair comparison in speed between the methods. Note that the value of 1e-3
which gives an error of 1% in Figure 6 (a) is the default in Matlab and corresponds to solving the differential equation with no step-size condition specified.
As a further contrast, instead of reducing the relative error tolerance until the errors are less than 0.1%, the maximum step size allowed in ode45 is reduced. Figure 7 shows the result for maximum step sizes less than 0.2 which is the value where the 90 th percentile error is oscillating around 1%. The curve is still noisy but follows a clear predictable trend of less variation as the error decreases, compared to Figure 6 which has no consistent trend and so is not as reliable. This result suggests that limiting the maximum step size is a more robust and reliable way of ensuring the error stays consistently low as compared to the faster way of reducing the relative tolerance. The dramatic differences between the responses in Figures 6 and 7 demonstrate the problem in managing error with "black box" differential equation solvers. These solvers are designed to solve every problem and hence cannot by definition, take advantage of a specific application. The approach of limiting the maximum step size was used in designing the original SPRINT system [13, 14] , and has been found to be the most reliable way in other applications with stiff systems [36] . Hence both methods of numerical error management are considered when comparing the CPU times versus the analytical method. To keep the error below the 0.1% cut off, the maximum step size is chosen to be 0.019. Table 6 shows the CPU times for both simulation methods applied on the 51 SPRINT patient cohort. Note that the average time taken for a simulation over an hour is 6.25e-6 seconds for the analytical method, compared to 0.035 and 0.9 seconds respectively for the numerical solver. The analytical simulation is thus significantly faster, by a factor of 5600 for the relative tolerance method and a factor of 144000 for the maximum step method.
Hence, for both cases, significant reductions in computational effort are made, enabling for more extensive virtual trials and Monte Carlo analyses. G S and the initial conditions are defined in Equation (84). In addition, a bolus and infusion of 1 unit are used respectively. The physiological values for the remaining parameters 2 3 , , Q n n k are unknown, since the model of Equations (75)- (77) has not been clinically validated. Therefore, to provide a mathematical test of the concept, the values of 2 n and Q k are chosen randomly in the same way as n and k in Equation (83) and 3 n is defined as 3 0.1 1.4 n = + δ, where δ is a uniform random number between 0 and 1. Steps 2-4 in Figure 3 are performed twice in each case, as further iterations were found to not
give any significant improvements.
After 1000 monte carlo simulations, the median error for this example was 0.16 % with a 90 th percentile of 0.42%, and no values were greater than 0.5%. These errors are greater than those in Tables 1-5 and Figure 5 , but this is expected since the analytical solution only solves Equations (75), (78) and (79) which is an approximation to Equations (75)-(77). As stated in the formulation of this general model, more accurate approximations to G and Q in Equation (76) could be used if required. However, errors are still significantly less than the expected measurement error of 7%, and the results demonstrate that the overall approach can be applied to more general glucose-insulin models.
Discussion and Conclusions
The concept of "Model-based Therapeutics" and the importance of fast forward simulation for enabling the rigorous testing of protocols were introduced in this paper.
For a non-linear glucose-insulin model an analytical solution was created by exploiting structure and partial analytical solutions in a subset of the model, then using an iterative approach to create the final solution. Analytical and closed form solutions were always found at each stage, by writing non-integrable functions in terms of integrable function approximations in physiological ranges. The function approximations were made over carefully chosen time points that adapt to significant changes in the patient parameters and thus maintaining a high degree of accuracy in the results.
The key idea was to tailor the solutions to the specific application which was the rapid calculation of glucose values only on the hour, given insulin bolus, infusion and feed inputs. Current methods are numerical, which compute the glucose values at every small time step within the hour, dramatically slowing down simulation speed, and hindering the number of protocols that could be tested. The application specific approach allows parameters or parts of solutions that are unchanged for long periods, to be pre-stored further reducing computation. For example expressions involving the population insulin clearance parameters n and k can be separated from the analytical solution and thus calculated only once before a full monte-carlo analysis. This de-coupling of expressions from the solution cannot be done in the standard numerical approach as all parameters and values are needed at every time step.
The analytical approach gave speed increases 5600-144000 times faster than the numerical based approach depending on the error management method used in the solver.
Very accurate solutions were found with 90 th percentile errors typically around 0.1-0.2% for all ranges of parameters within physiological constraints. The increased efficiency has had a significant impact on the ability to develop improved protocols, as turn around time has been massively improved and still only requires a simple programming language like
Matlab. In addition, the methods developed in this paper are general and could be applied to any type of glucose-insulin model as demonstrated by the accurate results for a more complex differential equation model. This modelled coupled the glucose to insulin in the plasma and interstitial insulin compartments, and the developed algorithms were readily adapted to this situation. Future work will look at applying this concept to other areas of bio-medical engineering for example cardiac modelling [32] [33] [34] [35] and insulin sensitivity testing [30, 39] .
